FDA Computer Software Assurance Guidance

The timing is tied directly to a major regulatory shift. A 2024 FDA final rule amended 21 CFR Part 820 to incorporate ISO 13485:2016 as the governing quality management standard, which took effect February 2, 2026, just one day before this guidance was issued. This guidance was updated to align recommendations with that newly operative regulatory framework.

As medical device manufacturing has grown increasingly reliant on automation, robotics, AI/ML tools, cloud computing, and digital systems, manufacturers needed clearer direction on how to validate this software. The traditional approach — exhaustive, documentation-heavy software validation — was seen as unnecessarily burdensome and ill-suited to modern, rapidly evolving technology. The FDA responded to industry requests for a more agile, practical framework.

The document introduces a risk-based "Computer Software Assurance" (CSA) framework that asks manufacturers to identify a software feature's intended use, assess whether a failure would foreseeably compromise patient safety (distinguishing "high process risk" from "not high process risk"), and then apply assurance activities — from lightweight exploratory testing to detailed scripted testing — proportionate to that risk. It also addresses electronic records requirements under 21 CFR Part 11 and includes four detailed worked examples covering a nonconformance management system, a learning management system, a business intelligence application, and a SaaS product lifecycle management system.